ISPUB.com / IJINT/1/1/4021
  • Author/Editor Login
  • Registration
  • Facebook
  • Google Plus

ISPUB.com

Internet
Scientific
Publications

  • Home
  • Journals
  • Latest Articles
  • Disclaimers
  • Article Submissions
  • Contact
  • Help
  • The Internet Journal of Interventional Medicine
  • Volume 1
  • Number 1

Original Article

Hypomagnesemia, Hyponatremia And Hypercholesterolemia On Admission As Prognostic Predictors For Patients With Subarachinoid Haemorrhage

A Saleh, M Megahed, K Ibrahim

Citation

A Saleh, M Megahed, K Ibrahim. Hypomagnesemia, Hyponatremia And Hypercholesterolemia On Admission As Prognostic Predictors For Patients With Subarachinoid Haemorrhage. The Internet Journal of Interventional Medicine. 2009 Volume 1 Number 1.

Abstract


BACKGROUND: A subarachnoid hemorrhage may occur spontaneously, usually from a ruptured cerebral aneurysm, or it may result from a head injury. It is a medical emergency and can lead to death or severe disability even when recognized and treated at an early stage. Up to half of all cases of SAH are fatal and 10–15% die before reaching a hospital, and those who survive often have neurological or cognitive impairment. The early prediction of outcome after subarachnoid hemorrhage is important for allocation of time and effort to patients with a more favorable prognosis. Magnesium is the second most prevalent intracellular cation. It plays important roles in maintaining both normal cellular and body functions. So its deficiency can have dramatic effects. It appears to increase the risk of strokes. Hypomagnesemia after subarachnoid hemorrhage is considered as a strong predictor for delayed cerebral ischaemia. Sodium plays a vital role in maintaining the concentration and volume of the extracellular fluid and a major determinant of extracellular fluid osmolality. Hyponatremia after subarachnoid hemorrhage potentially worsens the underlying neurological condition and probably increases the risk of mortality and morbidity. Hypercholesterolemia is a recognized major risk factor for endothelial vasomotor dysfunction in cerebral arterioles because its effects on large arterial vessels (atherosclerosis) increase the likelihood that tissues will experience an ischemic episode. Altered microvascular function during hypercholesterolemia produces exaggerated tissue responses to ischemia.AIM OF THE WORK: The aim of the presented study was correlation between hypomagnesemia, hyponatremia and hypercholesterolemia on admission in patients with subarachnoid hemorrhage and patients' outcome in the form of both morbidity and mortality according to the Glasgow outcome scale.PATIENTS AND METHODS: The study was conducted on 60 patients with subarachnoid hemorrhage who were admitted to the Critical Care Medicine Department at Alexandria Main University Hospital during the year 2009.Our results revealed that,RESULTS: In the present study, the age of patients with SAH ranged from 3-65 years with a mean age of 39.75 ±16.027. The present study revealed that there were no statistical significant differences between the outcome and the age of patients.The present study revealed that there were no statistical significant differences between the outcome and sex of the patient, in this study 21 patients (35.0%) were females and 39 patients (65.0%) were males.In the present study, traumatic subarachnoid hemorrhage constituted the main category of SAH (88.3%), followed by spontaneous subarachnoid hemorrhage (11.7%).The present study revealed that there was no significant relation between outcome and subarachnoid hemorrhage type either traumatic or spontaneous. The present study revealed that there was a statistical significant relationship between outcome and serum magnesium level on admission, we notice that, normomagnesemia was associated with better outcome than hypomagnesemia.The present study revealed that there was a statistical significant relationship between outcome and serum sodium level on admission, we notice that normonatremia was associated with better outcome than hyponatremia.The present study revealed that there was a statistical significant relationship between outcome and serum cholesterol level on admission, we notice that, normal cholesterol level was associated with better outcome than hypercholesterolemia.

 

Introduction

Subarachnoid haemorrhage presents urgent state in neurology, with dramatic clinical picture and high mortality, with a sequence of vasospasm and cerebral infarction.The pathophysiology of SAH involves a primary event and commonly a subsequent cascade of insults. The secondary cascade substantially contributes to morbidity and mortality as a sequence of vasospasm and cerebral infarction, (1-3) andssociated with clinically apparent delayed ischaemic neurological deficits (DID) in one-third of patients.

Vasospasm following SAH is considered reversible vasculopathy and appear to be due to structural and biochemical alteration at the level of the vascular endothelium and smooth muscle cells; mostly triggered by blood in the subarachinoid space.Cerebral infarction is a consequence of SAH-induced hypovolaemia and impaired cerebral autoregulatory functions with subsequent reduction in cerebral blood flow and cerebral perfusion. (4)

Therapeutic strategies rather than surgical intervention were employed to explore new prevention and treatment options; Nimodipine; a calcium channel antagonist; is so far the only available therapy with proven benefit for reducing the impact of DID.

Multiple drugs are usually implemented with different mechanisms of actions, has been studied in SAH and promising, the most ones are magnesium sulphate and 3-hydroxy-3-methylglutaryl-coA reductase inhibitors (statins).

Magnesium (Mg), one of the essential trace elements, plays important roles in maintaining both normal cellular and body functions. (5,6)Evidence has suggested that The beneficial mechanisms of Magnesium are multidirectional, it can protect neurons from ischemic damage and can support neuronal survival through various mechanisms, including noncompetitive inhibition of the release of presynaptic excitatory neurotransmitters, blocking of N-methyl-D-aspartate receptors (NMDA) channels and voltage-gated calcium channels, potentiation of presynaptic adenosine, suppression of cortical spreading depression and anoxic depolarization, potential as an antioxidant. (7,8)Additionally, magnesium is known to causes vascular smooth muscle to relax, thereby potentially increasing cerebral blood flow. (9)Recently, it has been reported that Mg has the potential to attenuate apoptosis by inhibiting DNA fragmentation factor and p53 gene expression and by altering the balance of proapoptotic bax to antiapoptotic bcl-2. (8)A number of studies have suggested that the level of free magnesium in the brain is an important factor in the development of secondary traumatic and ischaemic brain injury. In different models of experimental injury, the intracellular concentration of free magnesium declines after injury and the extent of this decline is correlated with poor outcome. (26)In the clinical situation, various studies have shown low concentrations of serum magnesium after traumatic brain injury. (3,4)The administration of magnesium after traumatic brain injury is neuroprotective and attenuates neuromotor dysfunction and cell death in the injured cortex and hippocampus. (10)

Some current studies consistent with an emerging body of literature suggesting that statins may improve outcome in preclinical models of intracranial hemorrhage, (11,12)as well as other forms of acute brain injury, such as subarachnoid hemorrhage (SAH) (13)and stroke. (14) These studies have strong potential for clinical translation. For example, based on data demonstrating that simvastatin reduced vasospasm and improved functional outcomes in a mouse subarachnoid hemorrhage (SAH) model.(13)

The class of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors has pleiotrophic effects that are independent of cholesterol metabolism. There are several potential mechanisms by which statins may have a palliative effect in the injured brain. In preclinical models of closed head injury, HMG CoA reductase inhibitors reduce glial activation and inflammatory responses (15) which contribute to cerebral edema and secondary neuronal injury. Statins may also reduce cerebral hypoperfusion via upregulation of endothelial nitric oxide synthase (eNOS) and stabilization of endothelial function.(13,16) This may be attributable to both upregulation of eNOS expression and improved stability of its activity by increasing availability of tetrahydrobiopterin, (17)a critical cofactor required for endothelial nitric oxide production. Statins may also reduce oxidative stress by inhibiting nicotinamide adenine dinucleotide phosphate (NADPH)-oxidase, a source of superoxide. (18)In addition to these acute effects, preclinical data suggest that long-term effects after injury may include enhanced neuronal plasticity, synaptogenesis, and angiogenesis.(19)

Hyponatremia occurred commonly (24%) in patients within 24 h after TBI&SAH.(20) Hyponatremia is associated with a variety of clinical signs or symptoms of neuronal dysfunction after many types of brain injury/illness, including traumatic brain injury (TBI), SAH. (21,22)It may increase post-traumatic vasospasm (23,24) promote vasogenic and/or cytotoxic brain edema, or interfere with cell volume homeostasis. (22-25)

There is a need for further studies to determine a risk factors that influence outcome in this population of patients, yet screening patients at risk for vasospasm and DID following SAH; including hypomagnesemia, hypercholesterolemia and hyponatremia on admission.

The aim of the present work was to study “the hypomagnesemia, hyponatremia and hypercholesterolemia as a prognostic predictors in patients with subarachinoid haemorrhage”.

Patients

This study was conducted on 60 adult patients admitted to the critical care unit in Alexandria Main University Hospital during the year 2009.

Inclusion criteria

All patients included in this work should fulfill the following criteria:

Patients presented with traumatic SAH.

Patients presented with aneurysmal SAH, multiple aneurysms and other vascular abnormalities such as Arterio-Venous Malformations (AVM).

Patients presented with GCS≥12. (26)

4. Patients presented with HUNT-HESS Scale≥3. (27,28)

Exclusion criteria

Patients presented with a major cardiac disease.

Patients presented with renal, hepatic or pulmonary disease.

Pregnant females.

patients was classified into

Group A: 30 patients suffering from SAH presented with hypomagnesemia, hyponatremia and hypercholesterlemia on admission.

Group B:30 patients suffering from SAH presented with normal serum levels of magnesium, sodium and cholesterol will serve as controls.

Methods

Informed consent will be taken from every patient included in this work or relatives as recommended by The Ethical Committee of Alexandria Faculty of Medicine.

This work will be conducted over two weeks during which the patients will be managed according to the conventional therapeutic strategies for SAH.

Patient's selection

To select patients admitted to the critical care unit with SAH, the followings will be done:

History of a new onset of neurological deficits, signs and symptoms of SAH such as:

(The classic symptom of subarachnoid hemorrhage is thunderclap headache “like being kicked in the head”, (29) Vomiting, seizures, (30) neck stiffness, other signs of meningism, confusion, decreased level of consciousness or coma may be present) either spontaneous or following head trauma.

Clinical examination and investigations to exclude a pre-existing cardiac, renal, hepatic or pulmonary disease such as ECG, renal function tests, liver function tests, chest x-ray and arterial blood gases.

CT-Brain compatible with the diagnosis of SAH.

Serum Mg, Na and Cholesterol levels on admission.

Patient monitoring

Along the duration of this work, the followings will be monitored:

Neurological deficits, signs and symptoms of SAH.

GCS and HUNT-HESS SCALE

Haemodynamic monitoring such as (heart rate-mean arterial blood pressure-body temperature).

Monitoring of the respiratory rate and oxygenation.

Monitoring of the renal and hepatic functions.

Serum Mg level: will be measured daily.

Serum Na level: will be measured daily.

Serum Cholesterol level: will be measured weekly.

Grouping

The selected patients will be classified into 2 groups; group A hypoMg, hypoNa and hypercholesterolemia on admission, and group B normal each on admission.

Figure 1

Outcome

To measure outcome in patients diagnosed with subarachnoid hemorrhage, assessment of the neurological outcome by accessing Glasgow Outcome Score. [Time Frame: 14 days].

Statistical Analysis

Statistics of the results were carried out according to the following formulae:

1. Arithmetic mean (X̅):

Was calculated as follows:

Figure 2

Where : x̅ = arithmetic mean

x = Sum of observations

n = number of observations

2. Standard deviation (SD):

Was calculated as follows:

Figure 3

Where: x2 = sum of squared observations.

(x)2 = square of the sum of observations.

n = number of observations.

3. “t” test:

Figure 4

Where: S2 p= Pooled variance.

S2 1= Variance of sample (1).

S2 2= Variance of sample (2).

n1 = Size of sample (1).

n2 = Size of sample (2).

X1 = Mean of sample (1).

X2 = Mean of sample (2).

S1 = Standard deviation of sample (1).

S2 = Standard deviation of sample (2).

5. Chi-square (X2):

For comparison between distribution of patients according to different items of study and use this formula for calculation:

Figure 5

p is significant if < 0.05

6. Fisher test (F-test)

Figure 6

S2 1= Variance for group 1

S2 1== Variance for group 2

Results

Age

Relation between outcome and age was presented in table (2), it shows that, there were no statistical significant differences between the outcome and age, P=0.473).

Figure 7
Table (1): Age distribution among the studied group

In the present study, the age of patients with SAH ranged from 3-65 years with a mean age of 39.75 ±16.027. Most of the patients (26cases, 43.3 %) were in the age group 20-39 years followed by those between 40-59 years (22 cases, 36.7%) followed by those >59 years (7 cases, 11.7%), and patients ≤19 years old (5 cases,8.3%).

Figure 8
Table (2): relation between outcome and age

Gender

This work was carried on 60 patients in which 21 patients (35.0%) were females and 39 patents (65.0%) were males.

Figure 9
Table (3): Gender distribution in the studied group

Relation between outcome and sex was presented in table (4), it shows that, there were no statistical significant differences between the outcome and patient’s sex, (P=0.593).

Figure 10
Table (4): Relation between outcome and sex

In this study 15 males (38.4%) have been died, 9 (23%) had become persistent vegetative, 9 (23%) had severe disability outcome , 5 (12.8%) had moderate disability outcome and one patient (2.5%) recovered, while 9 females (42.8%) have been died, 3 (14.2%) had become persistent vegetative, 3 (14.2%) had severe disability outcome, 4 (19%) had moderate disability outcome and 2 patients (9.5%) recovered.

SAH category

Figure 11
Table (5): Distribution of the category of SAH

This study was carried out on 60 patients with SAH where 53 (88.3%) patients presented with traumatic SAH and 7 (11.7%) patients presented with spontaneous SAH.

Relation between outcome and SAH category was presented in table (6), it showed that, there were no statistical significant differences between out come and the type of SAH, (P=0.801).

Figure 12
Table (6): Relation between outcome and category of SAH

The present study revealed that traumatic SAH was associated with less mortality rate than spontaneous SAH where patients with traumatic SAH had the following outcome, 21 patients (39.6%) have been died, 11 patients (20.7%) had become persistent vegetative, 11 patients (20.7%) had severe disability outcome ,7 patients (13.2%) had moderate disability outcome and 3 patients (5.7%) recovered. Whereas 3 (42.8%) patients suffered from spontaneous SAH have been died, one (14.2%) patient had become persistent vegetative, one (14.2%) patient had severe disability outcome, two (28.4%) patients had moderate disability outcome and no patient recovered.

GCS

Figure 13
Table(7): Distribution of the studied group regarding Glasgow Coma Score (GCS) on admission

Relation between outcome and GCS on admission was presented in table (6), it shows that, there were no statistical significant differences between outcome and GCS on admission, (P=0.068).

Figure 14
Table (8): relation between outcome and Glasgow Coma Score (GCS) on admission

The present study revealed that patients presented with GCS <8 on admission were 18 (30%) patients who had a mortality rate as 3 patients (16.7%), while 5 patient (27.8%) had become persistent vegetative, 6 patient (33.3%) had severe disability outcome, 4 patients (22.2%) had moderate disability outcome and no patient was recovered, while patients presented with GCS 8-12 on admission were 42 (70%) patients who had a mortality rate as21 patients (50%), while 7 patient (16.7%) had become persistent vegetative, 6 patient (14.2%) had severe disability outcome, 5 patients (12%) had moderate disability outcome and 3 patients (7.1%) were recovered.

H&H scale

Figure 15
Table(9): Distribution of the studied group regarding Hunt and Hess scale (H&H) on admission

The present work was carried on 60 patients suffered from SAH where 8 patients (13.3%) were presented with H&H scale ≤ 2 and 52 patients (86.7%) were presented with H&H scale ≤ 3.

Table (10) showed relation between outcome and H&H scale on admission, it illustrated that, there were no statistical significant differences between outcome and H&H scale, (P=0.118).

Figure 16
Table (10): Relation between outcome and Hunt and Hess scale (H&H) on admission

Patients with H&H scale ≤ 2 on admission had mortality rate as 6 patients (75%), one patient (12.5%) had become persistent vegetative, one patient (12.5%) recovered and no patient had become with severe disability or moderate disability outcome; while patients with H&H scale ≤ 3 on admission had mortality rate as 18 patients (34.6%), 11 patients (21.1%) had become persistent vegetative, 12 patients (23%) had severe disability outcome, 9 patients (17.3%) had moderate disability outcome and two patients (3.8%) recovered.

Mg

Table (11) showed relation between outcome and Serum magnesium level on admission, it demonstrated that, there was a statistical significant relationship between outcome and serum Mg level on admission, we notice that normal serum magnesium level was associated with better outcome than hypomagnesaemia, (P=0.050).

Figure 17
Table (11): relation between outcome and serum magnesium level on admission

The present work showed that mortality rate of Patients with serum magnesium <1.6 mg/dl on admission was 17 patients (56.7%), 6 patients (20%) had persistent vegetative outcome, 4 patients (13.3%) had severe disability outcome, 3 patients (10%) had moderate disability and no patient was recovered, where patients with S.Mg ≥1.6 mg/dl on admission had mortality rate as 7 patients were died (23.3%), 6 patients (20%) had a persistent vegetative outcome, 8 patients (26.7%) had severe disability outcome, 6 patients (20%) had moderate disability outcome and 3 patients (10%) had been recovered.

Na

Table (12) showed relation between outcome and serum sodium level on admission, it illustrated that, there was a statistical significant relationship between outcome and serum sodium level on admission, we notice that, Normonatremia was associated with better outcome than Hyponatremia, (P=0.001).

Figure 18
Table (12): relation between outcome and serum sodium level on admission

The present work showed that mortality rate of patients with serum sodium <135 meq/l on admission was 20 patients (66.7%), while 5 patients (16.7%) had persistent vegetative outcome, 3 patients (10%) had severe disability outcome, 2 patients (6.7%) had moderate disability outcome and no patient had been recovered, whereas patients with S.Na ≥135 meq/l on admission had mortality rate as 4 patients (13.3%), while 7 patients (23.3%) had persistent vegetative outcome, 9 patients (30%) severe disability outcome, 7 patients (23.3%) had become moderate disability and 3 patients (10%) had recovered.

Cholesterol

Table (13) showed relation between outcome and serum cholesterol level on admission, it demonstrated that, there was a statistical significant relationship between outcome and serum cholesterol level on admission, we notice that Normal serum cholesterol level was associated with better outcome than Hypercholesterolemia, (P=0.012).

Figure 19
Table (13): Relation between outcome and serum cholesterol level on admission:

The present work showed that mortality rate of patients with serum cholesterol ≥ 200 mg/dl on admission was 15 patients (50%), while two patients (6.7%) had persistent vegetative outcome, 9 patients (30%) had severe disability outcome, 4 patients (13.3%) had moderate disability outcome and no one had been recovered, while in patients with serum cholesterol <200 mg/dl on admission there were 9 patients (30%) died ,10 patients (33.3%) with persistent vegetative outcome, 3 patients (10%) had severe disability outcome, 5 patients (16.7%) had moderate disability outcome and 3 patients (10%) had become recovered.

GOS

Table (14) shows the distribution of the Glasgow Outcome Score (GOS) in the studied patients with SAH which describes the patients’ outcome after 14 days. The outcome of (3 patients, 5%) was good recovery, the outcome of (9 patients, 15%) was moderate disability, the outcome of (12 patients, 20%) was severe disability, while (12 patients, 20%) became vegetative and (24 patients,40%) has been died.

Figure 20
Table (14): Distribution of GOS score of the studied patients

Figure 21
Table (15): Predictor of outcome in the studied Patients

Figure 22

Discussion

This study was conducted on 60 adult patients males and non pregnant females who were admitted to the critical care unit in Alexandria Main University Hospital during 2009 diagnosed as subarachnoid hemorrhage.All patients included in this work known to be of no cardiac, renal, hepatic or pulmonary disease and presented with GCS ≥12 and H&H scale ≥3.Informed consent has been taken from every patient included in this work or relatives as recommended by The Ethical Committee of Alexandria Faculty of Medicine and this work conducted over two weeks. Patients had been classified into two Groups, Group A: 30 patients presented with hypomagnesemia, hyponatremia and hypercholesterlemia on admission and Group B: 30 patients presented with normal serum levels of magnesium, sodium and cholesterol as controls.

The present work showed that there was significant relation between serum magnesium on admission and the patient’s outcome, where Patients with serum magnesium<1.6 meq/l on admission had a worse Galascow Outcome Score than patients with serum magnesium ≥1.6 meq/l on admission.

The present work showed that mortality rate of patients with serum magnesium<1.6 meq/l on admission was 17 patients (56.7%), 6 patients (20%) had persistent vegetative outcome, 4 patients(13.3%) had severe disability outcome, 3 patients (10%) had moderate disability outcome and no patient (0%) was recovered, where patients with S.Mg ≥1.6 meq/l on admission had mortality rate as 7 patients were died (23.3%), 6 patients (20%) had a persistent vegetative outcome, 8 patients (26.7%) had severe disability outcome, 6 patients (20%) had moderate disability outcome and 3 patients (10%) had been recovered.

Van den Bergh WM,(31) et al,2003, assessed the relationship between hypomagnesemia and the severity of SAH and whether hypomagnesemia at admission or during the clinical course predicts delayed cerebral ischemia (DCI) and poor outcome, they found that hypomagnesemia at admission was associated with more cisternal and ventricular blood, a longer duration of unconsciousness, and a worse World Federation of Neurosurgical Societies score at admission. They also concluded that the crude risk for DCI with hypomagnesemia at admission was higher than after multivariate adjustment.

Reinhart RA(32) ,et al,1985, Rubeiz GJ(33),et al,1993 and Polderman KH(34),et al,2000, found that hypomagnesemia can occur in several cardiovascular and neurological emergencies, including cerebral infarction, head trauma, migraine, seizures, and preeclampsia, and it is associated with increased risk of death.

The present work showed that there was significant relation between serum sodium on admission and the patient’s outcome, where Patients with serum sodium <135meq/l on admission had a worse Galascow Outcome Score than patients with serum sodium ≥135meq/l on admission.

The present work showed that mortality rate of Patients with serum sodium<135 meq/l on admission was 20 patients(66.7%), 5 patients (16.7%) had persistent vegetative outcome, 3 patients(10%) had severe disability outcome, 2 patients (6.7%) had moderate disability outcome and no patient (0%) had been recovered, where patients with serum sodium ≥135 meq/l on admission had mortality rate of 4 patients(13.3%), 7 patients (23.3%) had persistent vegetative outcome, 9 patients (30%) severe disability outcome, 7 patients (23.3%) had become moderate disabled and 3 patients (10%) had been recovered.

Widjicks, et al(35) 1985, in their study 60% of SAH patients with hyponatremia developed cerebrovascular spasm whereas it was 12% in patients with normal serum sodium levels.

Hasan D,et al (36) 1990, only 24% of SAH patients with hyponatremia developed CVS.

Qureshi et al (37) 2002, did not find any correlation between hyponatremia and risk of CVS in patients with SAH.

The present work showed that there was significant relation between serum cholesterol on admission and the patient’s outcome, where patients with serum cholesterol >200 mg/dl on admission had a worse Galascow Outcome Score than patients with serum cholesterol <200 mg/dl on admission.

The present work showed that mortality rate of patients with serum cholesterol > 200 mg/dl on admission was 15 patients (50%), 2 patients (6.7%) had persistent vegetative outcome, 9 patients (30%) had severe disability outcome, 4 patients (13.3%) had moderate disability and no one (0%) had been recovered, while in patients with serum cholesterol <200 mg/dl on admission there were 9 patients (30%) died, 10 patients (33.3%) persistent vegetative outcome, 3 patients (10%) had severe disability outcome, 5 patients (16.7%) had moderate disability outcome and 3 patients (10%) had become recovered.

A trend toward an inverse association between serum cholesterol and the risk of SAH has been noted in some studies, Gatchev O, (38)et al, 1993, Leppäla JM, (39)et al, 1999, Mhurchu CN(40), et al, 2001, Ohkuma H,(41) et al, 2003 whereas in others no such relationship has been found, Iso H, (42)et al, 1989, Knekt P,(43) et al, 1991, Neaton JD(44), et al, 1993, Canhao P(45), et al, 1994, Teunissen LL(46), et al,1996.

Yano K, (47)et al,1989 Adamson, et al,1994, (48)asserted that atherosclerosis which may be aggravated by increased cholesterol concentration contributes to the rupture of cerebral aneurysms.

Inagawa Tet al, 2002 (49,50) concluded that, hypertension, cigarette smoking, and hypercholesterolemia were significantly more common in patients with SAH and independently associated with an increased risk of SAH. Where an increased concentration of cholesterol is the second most notable risk factor associated with SAH where hypertension was the most important risk factor.

Kelly R(51),et al:1989, Stehbens WE (52)et al,1989,London GM (53) ,et al, 1995, Safar M(54),et al,1997, ,Schievink WI(55)et al, 1997, Nichols WW(56), et al,1998,Wilkinson IB(57), et al, 1998, Benetos A(58), et al,1998, found that increasing age, smoking, hypertension, diabetes mellitus, hypercholesterolemia, and atherosclerosis, some of which are known to be associated with increased arterial stiffness (55,57) and cerebral aneurysms.(52)

In the present study, the age of patients with SAH ranged from 3-65 years with a mean age of 39.75 ±16.027. Most of the patients (26cases, 43.3 %) were in the age group 20-39 years followed by those between 40-59 years (22 cases, 36.7%) followed by those >59 years (7 cases, 11.7%) and patients <19 years old (5 cases, 8.3%).

The present study revealed that there was no significant relation between the age of patients with SAH and patients' outcome, where higher mortality rate was reported in the age group 20-39 years old as it was 10 patients (38.4%) followed by those between 40-59 years old it was 9 patients (40.9%) followed by those older than 59 years old 4 patients (57%) and 19 years old and younger it was one patient (20%), whereas recovery according to GOS was reported in those older than 59 years old as the higher rate of recovery which is (14.2%) followed by the age group 40-59 years old (4.5%) then the age group 20-39 years old (3.8%) and those < 19 years old it was (0% ) where no patient have been recovered.

The present study revealed that those in the age group 20-39 years old exhibit 10 patients (38.4%) died, 6 patients (23%) had become persistent vegetative ,6 (23%) patients had severe disability outcome, and 3 (11.5%) patients had moderate disability outcome and one patient (3.8%) was recovered, whereas those in the age group 40-59 years old exhibit 9 patients (40.9%) died, 2 (9%) patients had become persistent vegetative , 6 (27.2%) patients had severe disability outcome, and 4 (18%) patients had moderate disability outcome and one patients (4.5%) was recovered, whereas those in the age group >59 years old exhibit 4 patients (57%) died, one (14.2%) patients had become persistent vegetative, no patients had severe disability outcome, and one (14.2%) patients had moderate disability and one patients (14.2%) was recovered and those in the age group<19 years old exhibit one patient (20%) died, 3 (60%) patients had become persistent vegetative, no patients had severe disability outcome, and one (20%) patients had moderate disability outcome and no patients has been recovered.

Age as a risk factor for SAH was recorded by de Rooij NK et al (2007),(59) who found that the risk continues to rise with age and is 60% higher in the very elderly (over 85 years old) than in those between 45 and 55 years old and by Feigin VL et al. (2005)(60), who found that the group of people at risk for SAH is younger than the population usually affected by stroke, the risk still increases with age, young people are much less likely than middle aged people (risk ratio 0.1, or 10%) to suffer a subarachnoid hemorrhage.

The present study demonstrated that the mean age of the non survivors (40.93+ 15.443 years old) was higher than the mean age of the survivors (37.00+ 9.899years old). The more advanced the age groups the higher the mortality rate due to the process of senility and decreased reserve function of most organs. (61) Theses results were in concordance with those of the study of Thurman et al, (62) who stated that the non survivors were significantly older than the survivors. Jacobs et al, (63) had similar results with higher mean age of the non survivors than the survivors 52.0± 20.6 years and 49.7± 20.3 years respectively.

This study was carried out on 60 patients with SAH where 53 patients (88.3%) presented with traumatic SAH and 7 patients (11.7%) presented with spontaneous SAH.

The present work showed that there was no significant relation between type of SAH and the patient’s outcome.

The present study revealed that traumatic SAH was associated with less mortality rate than spontaneous SAH where patients with traumatic SAH had the following outcome, 21 patients (39.6%) have been died, 11 patients (20.7%) had become persistant vegetative,11 patients (20.7%) had severe disability outcome,7 patients (13.2%) had moderate disability outcome and 3 patients (5.7%) recovered, whereas 3 patients (42.8%) suffered from spontaneous SAH have been died, one patient (14.2%) had become persistant vegetative, one patient (14.2%) had severe disability outcome, two patients (28.4%) had moderate disability outcome and no patient was recovered.

This work was carried on 60 patients in which 21 patients (35.0%) were females and 39 patients (65.0%) were males.

The present work showed that there was no significant relation between sex and the patient’s outcome.

In this study 15 males (38.4%) have been died, 9 (23%) had become persistent vegetative, 9 (23%) had severe disability outcome ,5 (12.8%) had moderate disability outcome and one patient (2.5%) recovered, where 9 females (42.8%) have been died, 3 patients (14.2%) had become persistent vegetative, 3 patients (14.2%) had severe disability outcome, 4 patients (19%) had moderate disability outcome and 2 patients (9.5%) recovered.

In contrast to de Rooij NK,et al 2007(59), who found that Risk of SAH is about 25% higher in women.

The present work was carried on 60 patients suffered from SAH where 8 patients (13.3%) were presented with Hunt &Hess Scale (H&H) ≤ 2 and 52 patients (86.7%) were presented with Hunt &Hess Scale ≤ 3, with no significant relationship between H&H scale on admission and the patients’ outcome as revealed by the GOS of patients after 14 days. However patients with H&H scale ≤ 2 on admission had a mortality rate 6 patients (75%), one patient (12.5%) had become persistent vegetative, one patient (12.5%) recovered and no patient had become with severe disability or moderate disability; patients with H&H scale ≤ 3 on admission had a mortality rate 18 patients (34.6%), 11 patients (21.1%) had become persistent vegetative, 12 patient (23%) had severe disability outcome, 9 patients (17.3%) had Moderate disability outcome and two patients (3.8%) recovered.

Nakagawa T,(64) et al 2005, concluded that good and intermediate H&H scores (1, 2, and 3) on admission were associated with a favorable outcome, in their evaluation of the clinical factors to predict outcome in patients with a subarachnoid hemorrhage.

Although many methods of defining level of consciousness as indicator of brain damage exist, but the most widely used measure is The Glasgow Coma Scale (GCS) introduced by Teasdale and Jennett in 1974.(65) as it provides simple grading of the arousal and functional capacity of cerebral cortex in addition to predicting the outcome of the comatosed patients. However, Jagger, (66)stated that the predictive power of the GCS is derived mainly from the motor score, which easily affected by several factors in the Intensive Care Unit (ICU) such as sedation and muscle relaxants.

The present study revealed that there was a no significant relation between the GCS on admission and patients' outcome, where the patients presented with GCS <8 on admission were 18 (30%) patients who had a mortality rate 3 patients (16.7%), 5 patient (27.8%) had become persistent vegetative, 6 patient (33.3%) had severe disability outcome, 4 patients (22.2%) had moderate disability outcome and no patient (0%) was recovered, however, the patients presented with GCS 8-12 on admission were 42 (70%) patients who had a mortality rate 21 patients (50%), 7 patient (16.7%) had become persistent vegetative, 6 patient (14.2%) had severe disability outcome, 5 patients (12%) had moderate disability outcome and 3 patients (7.1%) were recovered.

Philip E.,(67) et al 2000, concluded that features that predict outcome in patients with subarachnoid hemorrhage (SAH) include densely packed intraventricular hemorrhage (IVH), hydrocephalus, and a Glasgow Coma Scale (GCS) score of less than 11 to 12 all predicting poor outcome.

This study was conducted on 60 patients presented with SAH, 38 patients were medically managed and 22 patients managed with surgical interventions. The all patients' outcome after 14 days were assessed by GOS where the outcome of (3 patients, 5%) was good recovery, the outcome of (9 patients, 15%) was moderate disability. The outcome of (12 patients, 20%) was severe disability, while (12 patients, 20%) became vegetative and (24 patients, 40%) has been died.

References

1. Witkop B. Paul Ehrlich and his magic bullets: revisited. Proc Am Philos Soc 1999; 143:540–57.
2. Thurman DJ, Alverson C, Dunn KA, Guerrero J, Sniezek JE. Traumatic brain injury in the United States: a public healthperspective. J Head Trauma Rehabil 1999; 14:602–15.
3. Witkop B. Paul Ehrlich and his magic bullets: revisited. Proc Am Philos Soc 1999; 143:540–57.
4. Ecker A, Riemenschneider PA. Arteriographic demonstration of spasm of the intracranial arteries. With special reference to saccular arterial aneurysms. J neurosurg1951; 8:660-7.
5. DohiK, OhtakiH, InnR, et al. Peroxynitrite and caspase-3expression after ischemia/reperfusion inmouse cardiac arrest model. ActaNeurochirSuppl 2003;86:87–91.
6. Vink R, McIntosh TK, Demediuk P, et al. Decline in intracellular free Mg2_ is associated with irreversible tissue injury after brain trauma. J Biol Chem 1988; 263:757–61.
7. McIntosh TK. Novel pharmacologic therapies in the treatment of experimental traumatic brain injury: a review. J Neurotrauma 1993; 10: 215–61.
8. Ustun ME, Duman A, Ogun CO, et al. Effects of nimodipine and magnesium sulfate on endogenous antioxidant levels in brain tissue after experimental head trauma. J Neurosurg Anesthesiol 2001; 13:227–32.
9. Memon ZI, Altura BT, Benjamin JL, Cracco RQ, Altura BM. Predictive value of serum ionized but not total magnesium levels in head injuries. Scand J Clin Lab Invest 1995; 55:671–7.
10. Enomoto T, Osugi T, Satoh H, et al. Pre-injury magnesium treatment prevents traumatic brain injury-induced hippocampal ERK activation, neuronal loss, and cognitive dysfunction in the radial-arm maze test. J Neurotrauma 2005; 22:783–92.
11. Jung KH, Chu K, Jeong SW, Han SY, Lee ST, Kim JY, Kim M, Roh JK. HMG-CoA reductase inhibitor, atorvastatin, promotes sensorimotor recovery, suppressing acute inflammatory reaction after experimental intracerebral hemorrhage. Stroke 2004; 35(7):1744–9.
12. Seyfried D, Han Y, Lu D, Chen J, Bydon A, Chopp M. Improvement in neurological outcome after administration of atorvastatin following experimental intracerebral hemorrhage in rats. J Neurosurg 2004; 101(1):104–7.
13. McGirt MJ, Lynch JR, Parra A, Sheng H, Pearlstein RD, Laskowitz DT, et al. Simvastatin increases endothelial nitric oxide synthase and ameliorates cerebral vasospasm resulting from subarachnoid hemorrhage. Stroke 2002; 33(12):2950–6.
14. Sironi L, Cimino M, Guerrini U, Calvio AM, Lodetti B, et al. Treatment with statins after induction of focal ischemia in rats reduces the extent of brain damage. Arterioscler Thromb Vasc Biol 2003; 23(2):322-7.
15. Wang H, Lynch JR, Song P, Yang HJ, Yates RB, Mace B, et al. Simvastatin and atorvastatin improve behavioral outcome, reduce hippocampal degeneration, and improve cerebral blood flow after experimental traumatic brain injury. Exp Neurol 2007; 206(1):59–69.
16. Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, Liao JK. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG) -CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 1998; 95(15):8880–5.
17. Hattori Y, Nakanishi N, Akimoto K, Yoshida M, Kasai K. HMG-CoA reductase inhibitor increases GTP cyclohydrolase I mRNA and tetrahydrobiopterin in vascular endothelial cells. Arterioscler Thromb Vasc Biol 2003; 23(2):176–82.
18. Erdos B, Snipes JA, Tulbert CD, Katakam P, Miller AW, Busija DW. Rosuvastatin improves cerebrovascular function in Zucker obese rats by inhibiting NAD (P) H oxidase-dependent superoxide production. Am J Physiol Heart Circ Physiol 2006; 290(3):1264–70.
19. Chen J, Zhang ZG, Li Y, Wang Y, Wang L, Jiang H, et al. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol 2003; 58(5):743–51.
20. Kirchhoff C, Stegmaier J, Bogner V, et al. Intrathecal and systemic concentration of NT-proBNP in patients with severe traumatic brain injury. J Neurotrauma 2006; 23:943–9.
21. Cole CD, Gottfried ON, Liu JK, Couldwell WT. Hyponatremia in the neurosurgical patient: diagnosis and management. Neurosurg Focus 2004; 16:1–10.
22. Bhardwaj A. Neurological impact of vasopressin dysregulation and hyponatremia. Ann Neurol 2006; 59:229–36.
23. Rabinstein AA, Wijdicks EFM. Hyponatremia in critically ill neurological patients. Neurologist 2003; 9:290–300.
24. Hasan D, Wijdicks EFM, Vermeulen M. Hyponatremia is associated with cerebral ischemia in patients with aneursymal subarachnoid hemorrhage. Ann Neurol 1990; 27:106–8.
25. Wehner F, Olsen H, Tinel H, Kinne-Saffran E, Kinne RKH. Cell volume regulation: osmolytes, osmolyte transport, and cell signal transduction. Rev Physiol Biochem Pharmacol 2003; 148:1–80. Lancet Neurol 2006; 7: 29–38.
26. Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A practical scale. Lancet 1974; 2:81-84.
27. Hunt WE, Hess RM. “Surgical risk as related to time of intervention in the repair of intracranialaneurysms.” Journal of Neurosurgery 1968 Jan; 28(1):14-20.
28. Hunt WE, Meagher JN, Hess RM. “Intracranial aneurysm. A nine-year study.” Ohio State Medical Journal 1966 Nov; 62(11):1168-71.
29. Longmore, Murray; Ian Wilkinson, Tom Turmezei, Chee Kay Cheung. Oxford Handbook of Clinical Medicine, 7th edition. Oxford University Press. 2007; pp. 841. ISBN 0-19-856837-1.
30. Van Gijn J, Kerr RS, Rinkel GJ. "Subarachnoid haemorrhage". Lancet. 2007; 369 (9558): 306–18.
31. van den Bergh WM, Algra A, van der Sprenkel JW, Tulleken CA, Rinkel GJ. Hypomagnesemia after aneurysmal subarachnoid hemorrhage. Neurosurgery 2003;52(2):276-82.
32. Reinhart RA, Desbiens NA: Hypomagnesemia in patients entering the ICU. Crit Care Med 13:506–507, 1985.
33. Rubeiz GJ, Thill-Baharozian M, Hardie D, Carlson RW: Association of hypomagnesemia and mortality in acutely ill medical patients. Crit Care Med 21:203–209, 1993.
34. Polderman KH, Bloemers FW, Peerdeman SM, Girbes AR: Hypomag-nesemia and hypophosphatemia at admission in patients with severe head injury. Crit Care Med 28:2022–2025, 2000.
35. Wijdicks EF, Vermeulen M, Hijdra A, van Gijn J. Hyponatremia and cerebral infarction in patients with ruptured intracranial aneurysms: is fluid restriction harmful? Ann Neurol 1985;17:137-40.
36. Hasan D, Wijdicks EF, Vermeulen M. Hyponatremia is associated with cerebral ischemia in patients with aneurysmal SAH. Ann Neurol 1990;27:106-8.
37. Qureshi AI, Suri MF, Sung GY, Straw RN, Yahia AM, Saad M, et al . Prognostic significance of hypernatremia and hyponatremia among patients with aneurysmal subarachnoid hemorrhage. Neurosurgery 2002;50:749-56.
38. 349.Gatchev O, Rastam L, Lindberg G, Gullberg B, Eklund GA, Isacsson SO: Subarachnoid hemorrhage, cerebral hemorrhage, and serum cholesterol concentration in men and women. Ann Epidemiol 3:403–409, 1993
39. 350. Leppäla JM, Virtamo J, Fogelholm R, Albanes D, Heinonen OP: Different risk factors for different stroke subtypes: association of blood pressure, cholesterol, and antioxidants. Stroke 30:2535–2540, 1999
40. 351. Mhurchu CN, Anderson C, Jamrozik K, Hankey G, Dunbabin D: Hormonal factors and risk of aneurysmal subarachnoid hemorrhage: an international population-based, case-control study. Stroke 32:606–612, 2001
41. 352. Ohkuma H, Tabata H, Suzuki S, Islam MS: Risk factors for aneurysmal subarachnoid hemorrhage in Aomori, Japan. Stroke 34:96–100, 2003
42. 353. Iso H, Jacobs DR Jr, Wentworth D, Neaton JD, Cohen JD: Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med 320:904–910, 1989
43. 354. Knekt P, Reunanen A, Aho K, Heliovaara M, Rissanen A, Aromaa A, et al: Risk factors for subarachnoid hemorrhage in a longitudinal population study. J Clin Epidemiol 44:933–939, 1991
44. 355. Neaton JD, Wentworth DN, Cutler J, Stamler J, Kuller L: Risk factors for death from different types of stroke. Multiple Risk Factor Intervention Trial Research Group. Ann Epidemiol 3:493–499, 1993
45. 356. Canhao P, Pinto AN, Ferro H, Ferro JM: Smoking and aneurysmal subarachnoid haemorrhage: a case-control study. J Cardiovasc Risk 1:155–158, 1994
46. 357. Teunissen LL, Rinkel GJ, Algra A, van Gijn J: Risk factors for subarachnoid hemorrhage: a systematic review. Stroke 27:544–549, 1996
47. 358 Yano K, Reed DM, MacLean CJ: Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program. Stroke 20:1460–1465, 1989
48. 359. Adamson J, Humphries SE, Ostergaard JR, Voldby B, Richards P, Powell JT: Are cerebral aneurysms atherosclerotic? Stroke 25:963–966, 1994
49. 360. Inagawa T: Seasonal variation in the incidence of aneurysmal subarachnoid hemorrhage in hospital- and community-based studies. J Neurosurg 96:497–509, 2002
50. 361. Inagawa T: Trends in incidence and case fatality rates of aneurysmal subarachnoid hemorrhage in Izumo City, Japan, between 1980–1989 and 1990–1998. Stroke 32:1499–1507, 2001
51. 362. Kelly R, Hayward C, Avolio A, et al: Noninvasive determination of age-related changes in the human arterial pulse. Circulation 80:1652–1659, 1989
52. 363. Stehbens WE: Etiology of intracranial berry aneurysms. J Neurosurg 70:823–831, 1989
53. 364. London GM, Guerin AP, Pannier B, et al: Influence of sex on arterial hemodynamics and blood pressure. Role of body height. Hypertension 26:514–519, 1995
54. 365. Benetos A, Safar M, Rudnichi A, et al: Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population. Hypertension 1997; 30:1410–1415.
55. 366. Schievink WI: Intracranial aneurysms. N Engl J Med 336:28–40, 1997
56. 367. Nichols WW, O'Rourke MF: McDonald's Blood Flow in Arteries. Theoretical, Experimental and Clinical Principles, ed 4. London: Arnold, 1998
57. 368. Wilkinson IB, Cockcroft JR, Webb DJ: Pulse wave analysis and arterial stiffness. J Cardiovasc Pharmacol 32 (Suppl 3):S33–S37, 1998
58. 369. Benetos A, Rudnichi A, Safar M, et al: Pulse pressure and cardiovascular mortality in normotensive and hypertensive subjects. Hypertension 32:560–564, 1998
59. de Rooij NK, Linn FH, van der Plas JA, Algra A, Rinkel GJ (December 2007). "Incidence of subarachnoid haemorrhage: A systematic review with emphasis on region, age, gender and time trends". Journal of Neurology, Neurosurgery, and Psychiatry 78 (12): 1365–72.
60. Feigin VL, Rinkel GJ, Lawes CM, et al. (2005). "Risk factors for subarachnoid hemorrhage: an updated systematic review of epidemiological studies". Stroke 36 (12): 2773–80.
61. Luerson TG, Klauber MR, Marshall LF. Outcome from head injury related to patient’s age: A longitudinal prospective study of adult and paediatric head injury. J Neurosurg 1988; 68:409-16.
62. Thurman DJ, Alverson C, Dunn KA, Guerrero J, Sniezek JE. Traumatic brain injury in the United States: a public health perspective. J Head Trauma Rehabil 1999; 14: 602-15.
63. Jacobs S, Zuleika M, Mphansa T: the Acute Physiology and Chronic Health Evaluation APACHE II score as a descriptive of patients' outcome compared with two other scoring systems. Crit Care Med 1999; 27(3): 741-4.
64. Nakagawa T, Suga S, Mayanagi K, Akaji K, Inamasu J, Kawase T; Predicting the overall management outcome in patients with a subarachnoid hemorrhage accompanied by a massive intracerebral or full-packed intraventricular hemorrhage: a 15-year retrospective study, Surg Neurol. 2005 Apr;63(4):329-34; discussion 334-5.
65. Teasdale G, Drake C, Hunt W, Kassell N, Sano K, Pertuiset B, De Villiers J (1988). "A universal subarachnoid hemorrhage scale: Report of a committee of the World Federation of Neurosurgical Societies". Journal of Neurology, Neurosurgery, and Psychiatry 51 (11): 1457.
66. Jagger J, Jane JA, Rimel R. The Glasgow Coma Scale: To sum or not to sum. Lancet 1983; 2:97
67. Philip E. Stieg, Packed Intraventricular Blood Strongly Predicts Outcome in SAH Journal Watch Neurology February 1, 2000

Author Information

Alaa Abd ElKader Saleh
Neurosurgery Department

Mohamed Mostafa Abd Elsalam Megahed
Critical Care Medicine Department

Khalil Hassan Ibrahim
Critical Care Medicine Department

Download PDF

Your free access to ISPUB is funded by the following advertisements:

 

 

BACK TO TOP
  • Facebook
  • Google Plus

© 2013 Internet Scientific Publications, LLC. All rights reserved.    UBM Medica Network Privacy Policy

Close

Enter the site

Login

Password

Remember me

Forgot password?

Login

SIGN IN AS A USER

Use your account on the social network Facebook, to create a profile on BusinessPress